AXIM Biotechnologies Secures Exclusive South Korean Distribution for TearScan Diagnostic Tests
AXIM Biotechnologies has partnered with VisionPlus Corp. to exclusively distribute its TearScan diagnostic tests in South Korea, expanding access to advanced ocular diagnostics in a market experiencing rising dry eye disease cases.
AXIM Biotechnologies, Inc. has entered into an exclusive distribution agreement with VisionPlus Corp. to market and distribute AXIM's TearScan Lactoferrin Test for detecting aqueous-deficient dry eye and TearScan IgE Test for ocular allergy throughout South Korea. The partnership grants VisionPlus exclusive rights to distribute both diagnostic tests, supported by the I-Peak digital reader, across the Korean market.
The companies will collaborate on Korean MFDS registration, targeting simultaneous submissions for both assays. VisionPlus will lead local compliance, regulatory coordination, and commercialization through its established network of ophthalmology clinics, hospitals, and specialty Dry Eye Centers. The agreement's initial term spans one year with automatic one-year renewals for an additional four years tied to annual sales milestones.
Catalina Valencia, President of AXIM Biotechnologies, emphasized the strategic importance of this partnership, stating that VisionPlus's clinical insight and national reach make them ideal to introduce AXIM's TearScan platform to South Korea. This collaboration will bring quantitative tear diagnostics directly to clinicians, improving diagnostic precision and enabling more personalized care for patients suffering from dry eye disease and ocular allergy.
Jerry Park, President of VisionPlus Corp., highlighted the growing need for advanced ocular diagnostics in South Korea, noting that years ago, VisionPlus recognized that the global rise in digital device use and worsening environmental conditions would lead to an epidemic of Dry Eye Disease. The company established dedicated Dry Eye Clinics across Korea in anticipation of that need, and AXIM's TearScan Lactoferrin and IgE tests will complete their vision of creating a one-stop diagnostic and treatment ecosystem.
AXIM's TearScan diagnostic portfolio provides quantitative, point-of-care tear biomarker analysis in minutes using a small tear sample. The system's reader delivers precise measurements that help clinicians differentiate between aqueous-deficient dry eye, evaporative dry eye, and allergic conjunctivitis. This distinction is crucial for selecting effective therapy and monitoring patient progress in a market where digital device usage and environmental factors continue to drive increased incidence of ocular conditions. For more information about AXIM's technology, visit https://www.aximbiotech.com.
Under the agreement, AXIM will retain manufacturing control, intellectual-property ownership, and provide regulatory and technical support for market entry and ongoing product quality compliance. This strategic expansion into South Korea represents a significant step in addressing the growing global demand for advanced ocular diagnostic solutions, particularly in markets experiencing rapid increases in dry eye disease prevalence due to environmental and lifestyle factors.